Difference between revisions of "Anastrozole (Arimidex)"
Jump to navigation
Jump to search
m |
m |
||
| Line 1: | Line 1: | ||
==General information== | ==General information== | ||
Class: Selective non-steroidal aromatase inhibitor<ref name="insert">[http://www1.astrazeneca-us.com/pi/arimidex.pdf Anastrozole (Arimidex) package insert]</ref><ref>[http://hemonc.org/docs/chemotherapypackageinsert/anastrozole.pdf Anastrozole (Arimidex) package insert (locally hosted backup)]</ref> | Class: Selective non-steroidal aromatase inhibitor<ref name="insert">[http://www1.astrazeneca-us.com/pi/arimidex.pdf Anastrozole (Arimidex) package insert]</ref><ref>[http://hemonc.org/docs/chemotherapypackageinsert/anastrozole.pdf Anastrozole (Arimidex) package insert (locally hosted backup)]</ref> | ||
| + | <br>Route: PO | ||
<br>Extravasation: n/a | <br>Extravasation: n/a | ||
Revision as of 00:48, 16 November 2011
General information
Class: Selective non-steroidal aromatase inhibitor[1][2]
Route: PO
Extravasation: n/a
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the package insert[1].
Patient drug information
Regimen
Anastrozole (Arimidex) 1mg PO daily (adjuvant, locally advanced, metastatic breast cancer)